Relation between Plasma Trough Concentration of Pazopanib and Progression-Free Survival in Metastatic Soft Tissue Sarcoma Patients

Relation between Plasma Trough Concentration of Pazopanib and Progression-Free Survival in Metastatic Soft Tissue Sarcoma Patients

Background: Pazopanib (PAZ) is an oral angiogenesis inhibitor approved to treat soft tissue sarcoma (STS) but associated with a large interpatient pharmacokinetic (PK) variability and narrow therapeutic index. We aimed to define the specific threshold of PAZ trough concentration (C<sub>min<...

Full description

Bibliographic Details
Main Authors: Marie-Sophie Minot-This, Pascaline Boudou-Rouquette, Anne Jouinot, Sixtine de Percin, David Balakirouchenane, Nihel Khoudour, Camille Tlemsani, Jonathan Chauvin, Audrey Thomas-Schoemann, François Goldwasser, Benoit Blanchet, Jérôme Alexandre
Format: Article
Language:English
Published: MDPI AG 2022-06-01
Series:Pharmaceutics
Subjects:
Pazopanib
pharmacokinetics
soft-tissue sarcoma
progression-free survival
toxicity
Online Access:https://www.mdpi.com/1999-4923/14/6/1224

Internet

https://www.mdpi.com/1999-4923/14/6/1224

Similar Items